TG Therapeutics Inc header image

TG Therapeutics Inc

TGTX

Equity

ISIN null / Valor 18511671

NASDAQ (2026-01-16)
USD 30.57-0.46%

TG Therapeutics Inc
UMushroom community rating:

star star star star star
5.00 1 votes No rating yet
NegativeNeutralPositive

About company

TG Therapeutics Inc is a biopharmaceutical company listed on the NASDAQ under the ticker symbol TGTX. The company focuses on developing innovative therapies for various diseases, with a particular emphasis on autoimmune and oncology conditions. One of its key products is BRIUMVI ® (ublituximab-xiiy), which is currently undergoing Phase 3 trials for the treatment of relapsing forms of multiple sclerosis (RMS). Through its research and development efforts, TG Therapeutics Inc aims to bring novel treatment options to patients in need.

Summarized from source with an LLMView SourceSector: Technology

Latest Results ():

Summarized from source with an LLMView Source

Key figures

4.91%1Y
124%3Y
-38.4%5Y

Performance

53.1%1Y
80.1%3Y
90.1%5Y

Volatility

Market cap

4853 M

Market cap (USD)

Daily traded volume (Shares)

2,499,003

Daily traded volume (Shares)

1 day high/low

32.3 / 31.23

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

5.00

1 votes
Performance:
starstarstarstarstar
5.00
Innovation:
starstarstarstarstar
5.00
Society:
starstarstarstarstar
5.00
Nature:
starstarstarstarstar
5.00
Luba Schoenig
Switzerland, 14 Jan 2025
star star star star star
On January 14, 2025, TG Therapeutics announced preliminary net revenue results for the fourth quarter and full year of 2024, along with anticipated development milestones for 2025. The company revised its guidance upward, driven by stronger-than-expected sales of its multiple sclerosis drug, Briumvi

EQUITIES OF THE SAME SECTOR

Compass Inc
Compass Inc Compass Inc Valor: 110359131
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.14%USD 12.86
Repligen Corp
Repligen Corp Repligen Corp Valor: 965900
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.20%USD 162.02
Universal Display Corp
Universal Display Corp Universal Display Corp Valor: 410257
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.86%USD 116.31
Novanta Inc
Novanta Inc Novanta Inc Valor: 32582414
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.04%USD 134.57
Semtech Corp
Semtech Corp Semtech Corp Valor: 969640
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.39%USD 77.56
Entain PLC
Entain PLC Entain PLC Valor: 11238866
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-3.27%GBP 7.03
TGS ASA
TGS ASA TGS ASA Valor: 680619
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.79%NOK 99.70
CML Microsystems PLC
CML Microsystems PLC CML Microsystems PLC Valor: 379170
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.00%GBP 2.65
Oracle Corp
Oracle Corp Oracle Corp Valor: 959184
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.65%USD 191.09
Paylocity Holding Corp
Paylocity Holding Corp Paylocity Holding Corp Valor: 23606709
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-1.09%USD 140.10